Imatinib Mesylate-Induced Lichen Planus and Plamoplantar Hyperkeratosis: A Case Report and Literature Review
Abstract
Imatinibmesylate is a tyrosine kinase inhibitor. Lichenoid reaction due to imatinibmesylate is rare. Most cases have cutaneous lesion with or without mucosal lesion. Mucosal involvement alone was rare. The length of time before the adverse effects appeared after the initiation of the drug ranged from one to six months. There have been few case reports with palmoplantar hyperkeratosis after one to seven months of imatinibmesylate treatment. Nail dystrophy was also present. This presented patient demonstrated cutaneous and mucosal lichenoid lesions as well as plamoplantar hyperkeratosis after taking imatinib for ten weeks. Histopathology was consistent with lichenoid reaction. Therefore it is important to recognize this side effect of imatinib for early diagnosis and treatment.
Keywords: Imatinib, lichenoid reaction, plamoplantar hyperkeratosis
Downloads
Published
How to Cite
Issue
Section
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
